Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hemangioma patient ( 0 \~ 9 months old)~* No treatment before~* 10 \~ 20 % volume increase in 2 \~ 4 weeks~* Hemangioma that caused organ function~* Hemangioma that will cause aesthetic problem~Exclusion Criteria:~* Cardiovascular disease (impossible to use propranolol)~* Drug adverse reaction or allergy history (propranolol, steroid)~* Bradycardia, Atrioventricular block, atrial block~* Cardiogenic Shock~* Right heart failure (pulmonary hypertension)~* Congestive heart failure~* Hypotension~* Peripheral nerve disease (moderate)~* Angina~* Hormone deficiency patient~* Pulmonary disease (asthma)~* diabetic ketoacidosis~* laser treatment history

- Gender: ALL
- Minimum Age: None
- Maximum Age: 9 Months
- Healthy Volunteers: f

Study Arms:
- Prednisolone (Type: ACTIVE_COMPARATOR): Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
- Propranolol (Type: EXPERIMENTAL): Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).